Prasterone - Paladin

Drug Profile

Prasterone - Paladin

Alternative Names: Dehydroepiandrosterone - Paladin; DHEA - Paladin; Fidelin

Latest Information Update: 28 Feb 2011

Price : $50

At a glance

  • Originator Beckman Research Institute
  • Developer Paladin Labs
  • Class Androstenols; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Cell differentiation stimulants; Cytokine inhibitors; DNA-directed RNA polymerase stimulants; Immunosuppressants; Intercellular signalling peptide and protein stimulants; Interleukin 2 stimulants; Protein synthesis stimulants; Testosterone congener stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Adrenal insufficiency; Alzheimer's disease; Andropause

Most Recent Events

  • 10 Jul 2006 Phase-II clinical trials in Adrenal insufficiency in Canada (unspecified route)
  • 10 Jul 2006 No development reported - Clinical-Phase-Unknown for Andropause in Canada (unspecified route)
  • 07 Jul 2004 Paladin intends to partner funding, development and commercialisation of prasterone in Europe, the US and Japan (http://www.paladinlabs.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top